Technical Analysis for MTNB - Matinas Biopharma Holdings, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.58 | -6.15% | -0.04 |
Earnings due: Nov 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New Downtrend | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 21 hours ago |
| Possible Inside Day | about 21 hours ago |
| 2x Volume Pace | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| 3x Volume Pace | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
Matinas Biopharma Holdings, Inc. Description
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Pharmaceutical Drugs Inflammation Infection Antibiotics Bacterial Infections Antimicrobial Resistance Aminoglycoside Drug Resistance Multiple Drug Resistance
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.5 |
| 52 Week Low | 0.5414 |
| Average Volume | 117,957 |
| 200-Day Moving Average | 8.28 |
| 50-Day Moving Average | 3.57 |
| 20-Day Moving Average | 3.06 |
| 10-Day Moving Average | 2.64 |
| Average True Range | 0.43 |
| RSI (14) | 15.25 |
| ADX | 27.51 |
| +DI | 11.97 |
| -DI | 52.31 |
| Chandelier Exit (Long, 3 ATRs) | 2.95 |
| Chandelier Exit (Short, 3 ATRs) | 1.84 |
| Upper Bollinger Bands | 4.94 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | -0.16 |
| BandWidth | 122.85 |
| MACD Line | -0.63 |
| MACD Signal Line | -0.35 |
| MACD Histogram | -0.2737 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.67 | ||||
| Resistance 3 (R3) | 0.67 | 0.64 | 0.65 | ||
| Resistance 2 (R2) | 0.64 | 0.62 | 0.64 | 0.65 | |
| Resistance 1 (R1) | 0.61 | 0.60 | 0.60 | 0.61 | 0.64 |
| Pivot Point | 0.58 | 0.58 | 0.57 | 0.58 | 0.58 |
| Support 1 (S1) | 0.55 | 0.56 | 0.54 | 0.55 | 0.52 |
| Support 2 (S2) | 0.52 | 0.55 | 0.52 | 0.52 | |
| Support 3 (S3) | 0.50 | 0.52 | 0.51 | ||
| Support 4 (S4) | 0.50 |
